Article and Video CATEGORIES

Cancer Journey

Search By

Ketki Patel, MHA, is a Program Operations Specialist/Post Award Specialist for the University of Washington Thoracic, Head and Neck Oncology Research Program in Seattle, Washington.

Ketki is an experienced Patient Financial Advocate with a demonstrated history of working with clinical trials/research, medical oncology, and holds knowledge in prior authorization of inpatient and outpatient chemotherapy and appealing all types of claim denials. She has experience working with the drug manufacturers for drug assistance and copay assistance in the hospital billing setting.

Copay Accumulators and Copay Maximizers
dbrock
Author
Ketki Patel, MHA, GRACE Guest Contributor
Copay Accumulators and Copay Maximizers

Copay accumulators and copay maximizers have gotten a lot of press lately, mostly bad press. I wanted to take the opportunity to provide some background on what this means for those with insurance plans that utilize this method of cost containment.

The problem:

Drug manufacturers and third party funding programs offer copay assistance funds when the costs are too high on certain medications, insurance companies that utilize a copay accumulator or copay maximizer option are basically saying that assistance will not apply toward your out of pocket maximum or copay amount and you still have to pay that full amount down from that assistance. The good news is if the copay assistance helps for the entire year then the issue won’t get out of hand, although you will still have to pay for your out of pocket on other medications and hopefully those are not as costly. However, if the funding is only provided for a portion of the year and you must stay on this medication for a while then the costs can add up quickly and it would be worth seeking other options.


Steps you can take to determine if this is the right option for you:

● Work with your financial navigator to determine if drug assistance or securing free drugs from the manufacturer may be an alternative to the copay assistance option if you will not be able to afford the copay at all

● A more time intensive option, but will help your state gain exposure to the limitations of your plan, I recommend escalating your case to the Insurance Commissioner of your state and a financial navigator can you help with this as well

● Work with your provider on any alternative treatment options

● Review your insurance plan and the information you receive from your employer as copay accumulators can be implemented by the organization negotiating your plan. Here is a link to some examples from 2019 https://aimedalliance.org/wp-content/uploads/2019/07/Copay-Accumulator-1-Pager.pdf

 
The good news:

Many organizations are working tirelessly to put an end to copay accumulators, most importantly ASCO has recently identified this issue as an area of concern as well. Many states have taken actions to address this rising issue as well. For example, Virginia and West Virginia’s laws require health plans to count third-party assistance towards an individual’s cost-sharing responsibilities on all occasions. Of note, Arizona has enacted a similar policy and many other states are following suit as well.

 

Do you have questions for Ketki?  Please join the conversation in our community forums! https://cancergrace.org/forum/how-combat-financial-toxicity-during-your-cancer-treatment-what-do-you-think


*Please note:  The below links are information only and GRACE has no relationship with these organizations.

Resources:

https://www.managedcaremag.com/voices/state-legislatures-spring-ahead-restrictions-drug-copay-accumulators https://lis.virginia.gov/cgi-bin/legp604.exe?191+ful+SB1596

http://leg1.state.va.us/cgi-bin/legp504.exe?191+ful+HB2515+pdf https://practice.asco.org/new-policy-brief-explains-how-co-pay-accumulators-maximizers-increase-cost-cancer-care-patients

 

 

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on